Autism Awareness Month has highlighted the focus on underlying biological mechanisms that influence autism and nervous system conditions.
HMGB1 as a common biomarker in autism and nervous system diseases Read More »
Has been underscored HMGB1’s potential as a strategic target for therapeutic intervention in chronic kidney diseases (CKD).
Kidney Diseases: HMGB1 as a Potential Therapeutic Strategy Read More »
Among others, HMGB1 protein has been identified for its significant role in the pathology of autism and neurological conditions.
Unraveling Autism’s complexities through Epigenetics and Neuroimmunology Read More »
A relevant research concerning a wider perspective on protective immunity has just been published: Maura Casalgrandi, researcher in HMGBiotech, is one of the authors involved in the study.
Recent insights reveal HMGB1’s central function in regulating the interplay between autophagy and apoptosis, processes essential for maintaining cellular homeostasis and determining the fate of cancer cells.
Recent findings illuminate a crucial pathway from fatty liver disease to hepatocellular carcinoma (HCC), where High Mobility Group Box 1 (HMGB1) emerges as a crucial player in the progression of liver diseases.
As we commemorate World Cancer Day, it’s crucial to spotlight groundbreaking researches that drive our path to discovery cancer mechanism.
The dual role of HMGB1 in Cancer Immunity and its potential in immunotherapy Read More »
The quest to accurately quantify High Mobility Group Box 1 (HMGB1) and its redox variants in human plasma has been a challenging endeavor in biomedical research, due to the complexities presented by interference from other proteins and autoantibodies.
Since its discovery, 50 years ago, the role of HMGB1 protein has shift from mere structural protein in chromatin, to be considered as a key factor in new therapeutic approaches to diseases, such as intracranial aneurysms.
Highlighting HMGB1’s Role in Intracranial Aneurysms Read More »